MAP2K7 and neoplasm: However, although recognized targets, such as p-MEK/p-ERK signaling pathway, as well as VEGFR and PDGFR, which could be directly and indirectly modulated by sorafenib to inhibit tumor growth, distinct therapeutic value in individual patient could still be observed that may be caused by the different targets in different patient groups [5].